Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PolyMedica settles Medicare over-billing charges

This article was originally published in The Gray Sheet

Executive Summary

Tentative settlement with the Department of Justice will include a $35 mil. payment and a corporate integrity agreement without admission of wrongdoing, the firm says. The deal follows a three-year DoJ investigation into the company's Medicare billing and claims documentation practices. "It's important to note the agreements are still being negotiated and are subject to approval by the OIG and DoJ," PolyMedica Chairman Samuel Shanaman says in a release. The diabetes and respiratory product firm notes that the U.S. Attorney's Office for the Southern District of Florida "will not bring criminal charges against the company" (1"The Gray Sheet" Feb. 16, 2004, p. 12)...

You may also be interested in...



PolyMedica Explains Medicare Over-Billing, Accrues Reserves For Repayment

PolyMedica will seek growth through acquisitions to offset an average 3% reduction in reimbursement rates for its diabetes products that will become effective in 2005 under the recent Medicare law

Industry Asks If Small Business Loan Relief Applies To Companies With Equity Investors

A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

UsernamePublicRestriction

Register

MT021154

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel